Table 2.
MR results of causal links between gut microbiome and metabolites/metabolite ratios based on M-mCRC
| Gut microbiome | ID | Metabolites/Metabolite ratios | Super_pathway | Sub_pathway | Nsnp | Methods | OR(95%CI) | p−value |
|---|---|---|---|---|---|---|---|---|
| genus.Eubacteriumhalliigroup.id.11338 | GCST90199716 | 10-undecenoate (11:1n1) levels | Lipid | Medium Chain Fatty Acid | 12 | Inverse variance weighted (fixed effects) | 1.18(1.01,1.38) | 0.0324 |
| 12 | Inverse variance weighted (multiplicative random effects) | 1.18(1.01,1.38) | 0.0321 | |||||
| 12 | Weighted median | 1.20(0.97,1.49) | 0.0953 | |||||
| 12 | MR Egger | 1.09(0.77,1.52) | 0.6442 | |||||
| 12 | Simple median | 1.24(1.02,1.51) | 0.0329 | |||||
| GCST90200901 | Ornithine to phosphate ratio | Amino Acid / Energy | / | 12 | Inverse variance weighted (fixed effects) | 1.30(1.11,1.50) | 0.0007 | |
| 12 | Inverse variance weighted (multiplicative random effects) | 1.30(1.12,1.50) | 0.0005 | |||||
| 12 | Weighted median | 1.16(0.94,1.43) | 0.1709 | |||||
| 12 | MR Egger | 1.34(0.97,1.85) | 0.1100 | |||||
| 12 | Simple median | 1.16(0.94,1.42) | 0.1652 | |||||
| genus.Butyrivibrio.id.1993 | GCST90199727 | 1-oleoyl-GPC (18:1) levels | Lipid | Lysophospholipid | 13 | Inverse variance weighted (fixed effects) | 0.90(0.84,0.97) | 0.0079 |
| 13 | Inverse variance weighted (multiplicative random effects) | 0.90(0.84,0.98) | 0.0110 | |||||
| 13 | Weighted median | 0.93(0.83,1.03) | 0.1819 | |||||
| 13 | MR Egger | 0.98(0.69,1.39) | 0.9046 | |||||
| 13 | Simple median | 0.93(0.84,1.03) | 0.1707 | |||||
| GCST90200971 | Leucine to phosphate ratio | Amino Acid / Energy | / | 13 | Inverse variance weighted (fixed effects) | 0.92(0.86,0.99) | 0.0221 | |
| 13 | Inverse variance weighted (multiplicative random effects) | 0.92(0.87,0.98) | 0.0089 | |||||
| 13 | Weighted median | 0.92(0.84,1.01) | 0.0873 | |||||
| 13 | MR Egger | 0.71(0.53,0.96) | 0.0476 | |||||
| 13 | Simple median | 0.92(0.83,1.02) | 0.1000 | |||||
| GCST90201012 | 3-methyl-2-oxovalerate to 3-methyl-2-oxobutyrate ratio | Amino Acid / Amino Acid | / | 13 | Inverse variance weighted (fixed effects) | 0.91(0.85,0.98) | 0.0151 | |
| 13 | Inverse variance weighted (multiplicative random effects) | 0.91(0.85,0.98) | 0.0110 | |||||
| 13 | Weighted median | 0.94(0.85,1.05) | 0.2593 | |||||
| 13 | MR Egger | 0.90(0.65,1.24) | 0.5329 | |||||
| 13 | Simple median | 0.94(0.85,1.04) | 0.2243 | |||||
| GCST90201016 | Bilirubin (Z,Z) to etiocholanolone glucuronide ratio | Cofactors and Vitamins / Lipid | / | 13 | Inverse variance weighted (fixed effects) | 0.87(0.81,0.94) | 0.0004 | |
| 13 | Inverse variance weighted (multiplicative random effects) | 0.87(0.80,0.94) | 0.0009 | |||||
| 13 | Weighted median | 0.87(0.78,0.97) | 0.0097 | |||||
| 13 | MR Egger | 0.73(0.51,1.04) | 0.1122 | |||||
| 13 | Simple median | 0.87(0.78,0.97) | 0.0110 | |||||
| genus.Catenibacterium.id.2153 | GCST90199790 | 2-palmitoleoyl-GPC (16:1) levels | Lipid | Lysophospholipid | 4 | Inverse variance weighted (fixed effects) | 0.85(0.73,0.98) | 0.0233 |
| 4 | Inverse variance weighted (multiplicative random effects) | 0.85(0.78,0.92) | 0.0001 | |||||
| 4 | Weighted median | 0.86(0.73,1.02) | 0.0768 | |||||
| 4 | MR Egger | 1.03(0.17,6.31) | 0.9760 | |||||
| 4 | Simple median | 0.86(0.73,1.01) | 0.0669 | |||||
| genus.Oxalobacter.id.2978 | GCST90199855 | 5alpha-androstan-3beta,17beta-diol monosulfate (2) levels | Lipid | Androgenic Steroids | 8 | Inverse variance weighted (fixed effects) | 1.19(1.07,1.32) | 0.0012 |
| 8 | Inverse variance weighted (multiplicative random effects) | 1.19(1.05,1.34) | 0.0051 | |||||
| 8 | Weighted median | 1.12(0.97,1.29) | 0.1267 | |||||
| 8 | MR Egger | 1.38(0.78,2.46) | 0.3102 | |||||
| 8 | Simple median | 1.13(0.98,1.30) | 0.0891 | |||||
| genus.Ruminiclostridium5.id.11355 | GCST90200033 | Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) levels | Lipid | Sphingomyelins | 6 | Inverse variance weighted (fixed effects) | 0.81(0.65,1.01) | 0.0670 |
| 6 | Inverse variance weighted (multiplicative random effects) | 0.81(0.67,0.98) | 0.0278 | |||||
| 6 | Weighted median | 0.87(0.66,1.15) | 0.3329 | |||||
| 6 | MR Egger | 0.95(0.37,2.42) | 0.9129 | |||||
| 6 | Simple median | 0.84(0.63,1.12) | 0.2261 | |||||
| GCST90200116 | Ceramide (d18:1/14:0, d16:1/16:0) levels | Lipid | Ceramides | 6 | Inverse variance weighted (fixed effects) | 0.78(0.59,1.02) | 0.0683 | |
| 6 | Inverse variance weighted (multiplicative random effects) | 0.78(0.63,0.97) | 0.0226 | |||||
| 6 | Weighted median | 0.73(0.52,1.03) | 0.0760 | |||||
| 6 | MR Egger | 1.49(0.48,4.60) | 0.5301 | |||||
| 6 | Simple median | 0.71(0.50,1.02) | 0.0658 | |||||
| phylum.Proteobacteria.id.2375 | GCST90200051 | 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels | Lipid | Phosphatidylcholine (PC) | 7 | Inverse variance weighted (fixed effects) | 0.80(0.65,1.00) | 0.0506 |
| 7 | Inverse variance weighted (multiplicative random effects) | 0.80(0.68,0.95) | 0.0123 | |||||
| 7 | Weighted median | 0.78(0.59,1.04) | 0.0928 | |||||
| 7 | MR Egger | 0.54(0.30,0.99) | 0.1032 | |||||
| 7 | Simple median | 0.79(0.59,1.06) | 0.1124 | |||||
| GCST90200226 | 5-hydroxy-2-methylpyridine sulfate levels | Xenobiotics | Chemical | 7 | Inverse variance weighted (fixed effects) | 0.74(0.58,0.94) | 0.0134 | |
| 7 | Inverse variance weighted (multiplicative random effects) | 0.74(0.59,0.92) | 0.0064 | |||||
| 7 | Weighted median | 0.76(0.55,1.06) | 0.1047 | |||||
| 7 | MR Egger | 0.69(0.36,1.34) | 0.3201 | |||||
| 7 | Simple median | 0.76(0.54,1.06) | 0.1078 | |||||
| genus.Olsenella.id.822 | GCST90200264 | Bilirubin degradation product, C17H20N2O5 (2) levels | Partially Characterized Molecules | Partially Characterized Molecules | 8 | Inverse variance weighted (fixed effects) | 1.14(1.03,1.26) | 0.0130 |
| 8 | Inverse variance weighted (multiplicative random effects) | 1.14(1.03,1.26) | 0.0136 | |||||
| 8 | Weighted median | 1.08(0.94,1.23) | 0.2745 | |||||
| 8 | MR Egger | 1.04(0.67,1.60) | 0.8750 | |||||
| 8 | Simple median | 1.08(0.95,1.24) | 0.2449 | |||||
| GCST90200265 | Bilirubin degradation product, C16H18N2O5 (4) levels | Partially Characterized Molecules | Partially Characterized Molecules | 8 | Inverse variance weighted (fixed effects) | 1.12(1.01,1.24) | 0.0270 | |
| 8 | Inverse variance weighted (multiplicative random effects) | 1.12(1.02,1.23) | 0.0169 | |||||
| 8 | Weighted median | 1.15(1.00,1.31) | 0.0473 | |||||
| 8 | MR Egger | 1.26(0.84,1.90) | 0.3010 | |||||
| 8 | Simple median | 1.15(1.00,1.31) | 0.0421 | |||||
| GCST90200269 | Bilirubin degradation product, C17H20N2O5 (1) levels | Partially Characterized Molecules | Partially Characterized Molecules | 8 | Inverse variance weighted (fixed effects) | 1.13(1.02,1.25) | 0.0168 | |
| 8 | Inverse variance weighted (multiplicative random effects) | 1.13(1.02,1.25) | 0.0159 | |||||
| 8 | Weighted median | 1.07(0.94,1.23) | 0.2988 | |||||
| 8 | MR Egger | 1.05(0.68,1.61) | 0.8388 | |||||
| 8 | Simple median | 1.08(0.95,1.24) | 0.2352 | |||||
| genus.Faecalibacterium.id.2057 | GCST90200335 | Stearoyl sphingomyelin (d18:1/18:0) levels | Lipid | Sphingomyelins | 7 | Inverse variance weighted (fixed effects) | 0.79(0.67,0.94) | 0.0080 |
| 7 | Inverse variance weighted (multiplicative random effects) | 0.79(0.63,0.99) | 0.0415 | |||||
| 7 | Weighted median | 0.87(0.68,1.11) | 0.2571 | |||||
| 7 | MR Egger | 0.97(0.66,1.44) | 0.8984 | |||||
| 7 | Simple median | 0.72(0.54,0.97) | 0.0313 | |||||
| GCST90201012 | 3-methyl-2-oxovalerate to 3-methyl-2-oxobutyrate ratio | Amino Acid / Amino Acid | / | 7 | Inverse variance weighted (fixed effects) | 1.32(1.11,1.57) | 0.0019 | |
| 7 | Inverse variance weighted (multiplicative random effects) | 1.32(1.07,1.63) | 0.0099 | |||||
| 7 | Weighted median | 1.38(1.07,1.77) | 0.0123 | |||||
| 7 | MR Egger | 1.27(0.84,1.93) | 0.3047 | |||||
| 7 | Simple median | 1.37(1.03,1.81) | 0.0307 |